Janssen taps Daman to develop app for psoriatic arthritis trial

By Nick Taylor

- Last updated on GMT

(Jacques Hugo/iStock via Getty Images Plus)
(Jacques Hugo/iStock via Getty Images Plus)

Related tags Mobile app Patient centricity Data management Patient reported outcomes Decentralized trials Janssen

The division of Johnson and Johnson has selected the health tech company to create a mobile app to be used to collect data in a psoriatic arthritis trial.

Daman, a Danish digital healthcare company, has been selected by Janssen to develop an app to collect patient-reported outcomes (PROs) in a psoriatic arthritis study. The company previously developed RheumaBuddy, an app for Apple and Android devices that is designed to help rheumatoid arthritis patients self-manage their disease; the new app will use the RheumaBuddy concept to enable Janssen to collect data on patients enrolled in a psoriatic arthritis clinical trial.

The app will capture patient-reported outcomes for assessing psoriatic arthritis’ impact on patients in everyday life. We will use validated PROs, and moreover continuously capture data points such as mood, fatigue, itchiness, stiffness, by patient assessment, and sleep and activity, automatically captured with the use of a medically-validated smartwatch​,” said a spokesperson for Daman.

Through the app, Daman aims to provide patients with a valuable tool and Janssen with a way to obtain longitudinal data-driven insights on the lives of the people living with psoriatic arthritis who enroll in the clinical trial.

Clinical trial sponsors have used PROs to capture insights into aspects of the lives of patients such as mood, fatigue, itchiness, and stiffness for years. However, site-based data capture has limitations that the app is intended to address.

Studies have shown that ‘biases’ are present when asking patients to fill out PROs while in the clinic, and this concept is referred to as ecological momentary assessment. Moreover, we are able to capture PROs more frequently, thereby increasing the depth of insights into patients’ everyday life. Applied in a clinical trial, this can both lead to deeper data-driven understanding of patients' lives, and reveal different outcomes on everyday life between different treatments​,” said the spokesperson.

The spokesperson cited the fact in-app PROs are “very cost-efficient​” and have “high accuracy​” as other advantages of the technology.

Jan Koren, president at EUROPSO, the federation of psoriasis patients’ associations in Europe, has taken part in the co-creation process. The aim has been to create an app that works for patients with psoriatic arthritis, a condition that affects 5m people in Europe and causes physical and psychological impacts that negatively affect quality of life.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us